Thrombospondin 1 Improves Hepatic Steatosis in Diet-induced Insulin-resistant Mice and is Associated with Hepatic Fat Content in Humans

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2020 Jun 25

PMID 32580141

Citations 19

Authors

Jinyun Bai

Mingfeng Xia

Yaqian Xue

Fengguang Ma

Aoyuan Cui

Yixuan Sun

Yamei Han

Xi Xu

Feifei Zhang

Zhimin Hu

Zhengshuai Liu

Yuxiao Liu

Genxiang Cai

Weitong Su

Xiaoyang Sun

Haifu Wu

Hongmei Yan

Xinxia Chang

Xiqi Hu

Hua Bian

Pu Xia

Jing Gao

Yu Li

Xin Gao

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is associated with altered production of secreted proteins. Increased understanding of secreted proteins could lead to improved prediction and treatment of NAFLD. Here, we aimed to discover novel secreted proteins in humans that are associated with hepatic fat content using unbiased proteomic profiling strategy, and how the identified Thbs1 modulates lipid metabolism and hepatic steatosis.

Method: NAFLD patients were enrolled and treated with lifestyle intervention. Patients who underwent liver biopsy were enrolled for analyzing the correlation between circulating Thbs1 and liver steatosis. Mice were fed on high-fat, high-sucrose diet and treated with recombinant Thbs1. Primary hepatocytes isolated from CD36 knockout (CD36-/-) mice and their wild-type littermates (controls) were treated with glucose plus insulin for 24 h together with or without recombinant Thbs1.

Finding: Serum Thbs1 levels are increased in participants with NAFLD and positively associated with liver steatosis grades. Improvement of liver steatosis after lifestyle intervention was accompanied with significant reduction of serum Thbs1 levels. Pharmacological administration of recombinant human Thbs1 attenuates hepatic steatosis in diet-induced obese mice. Treatment with Thbs1 protein or stably overexpression of Thbs1 causes a significant reduction of lipid accumulation in primary hepatocytes or HepG2 cells exposed to high glucose plus insulin, suggesting that Thbs1 regulates lipid metabolism in a hepatocyte-autonomous manner. Mechanistically, Thbs1 inhibits cleavage and processing of SREBP-1, leading to a reduction of target lipogenic gene expression and hepatic steatosis. Inhibitory effects of Thbs1 on lipogenesis and triglyceride accumulation are abrogated in CD36 deficient primary hepatocytes exposed to high glucose plus insulin. Interestingly, beneficial effects of Thbs1 on lipid accumulation are observed in primary hepatocytes treated with a Thbs1 nonapeptide mimetic ABT-526.

Interpretation: Thbs1 is a biomarker for NAFLD in humans, and pharmacological and genetic approaches for the modulation of Thbs1 activity may have the therapeutic potential for treating hepatic steatosis. FUND: A full list of funding bodies that contributed to this study can be found in the Funding Sources section.

Citing Articles

Single-cell RNA sequencing reveals the heterogeneity of MYH11+ tumour-associated fibroblasts between left-sided and right-sided colorectal cancer.

Wang C, Zhao Y, Zhang S, Du M, He G, Tan S J Cell Mol Med. 2024; 28(18):e70102.

PMID: 39294858 PMC: 11410558. DOI: 10.1111/jcmm.70102.

Adipose stem cells-derived small extracellular vesicles transport Thrombospondin 1 cargo to promote insulin resistance in gestational diabetes mellitus.

Li H, Yang H, Liu J, Yang H, Gao X, Yang X Diabetol Metab Syndr. 2024; 16(1):105.

PMID: 38764083 PMC: 11103858. DOI: 10.1186/s13098-024-01276-1.

Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice.

Ling C, Liu S, Wang Y, Huo G, Yang Y, Xu N Zool Res. 2024; 45(3):551-566.

PMID: 38757223 PMC: 11188599. DOI: 10.24272/j.issn.2095-8137.2024.002.

Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.

Boccatonda A, Del Cane L, Marola L, DArdes D, Lessiani G, Di Gregorio N Life (Basel). 2024; 14(4).

PMID: 38672744 PMC: 11051088. DOI: 10.3390/life14040473.

Identification of genetic drivers of plasma lipoprotein size in the Diversity Outbred mouse population.

Price T, Emfinger C, Schueler K, King S, Nicholson R, Beck T J Lipid Res. 2023; 64(12):100471.

PMID: 37944753 PMC: 10750189. DOI: 10.1016/j.jlr.2023.100471.

References

Baenziger N, Brodie G, MAJERUS P . A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci U S A. 1971; 68(1):240-3. PMC: 391203. DOI: 10.1073/pnas.68.1.240. View

Asch A, Barnwell J, Silverstein R, Nachman R . Isolation of the thrombospondin membrane receptor. J Clin Invest. 1987; 79(4):1054-61. PMC: 424283. DOI: 10.1172/JCI112918. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

Inoue M, Jiang Y, Barnes 2nd R, Tokunaga M, Martinez-Santibanez G, Geletka L . Thrombospondin 1 mediates high-fat diet-induced muscle fibrosis and insulin resistance in male mice. Endocrinology. 2013; 154(12):4548-59. PMC: 3836064. DOI: 10.1210/en.2013-1587. View

Isenberg J, Yu C, Roberts D . Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol. 2007; 75(4):875-82. PMC: 2267764. DOI: 10.1016/j.bcp.2007.10.025. View

Kawano Y, Cohen D . Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48(4):434-41. PMC: 3633701. DOI: 10.1007/s00535-013-0758-5. View

Yamaguchi K, Yang L, McCall S, Huang J, Yu X, Pandey S . Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007; 45(6):1366-74. DOI: 10.1002/hep.21655. View

Wilfred de Alwis N, Day C . Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 Suppl 1:S104-12. DOI: 10.1016/j.jhep.2008.01.009. View

10.

Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J . Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol Ther. 2011; 13(2):149-55. DOI: 10.1089/dia.2010.0101. View

11.

Griffin N, Yu J, Long F, Oh P, Shore S, Li Y . Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol. 2009; 28(1):83-9. PMC: 2805705. DOI: 10.1038/nbt.1592. View

12.

Febbraio M, Abumrad N, Hajjar D, Sharma K, Cheng W, Pearce S . A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999; 274(27):19055-62. DOI: 10.1074/jbc.274.27.19055. View

13.

Li Y, Xu S, Mihaylova M, Zheng B, Hou X, Jiang B . AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011; 13(4):376-388. PMC: 3086578. DOI: 10.1016/j.cmet.2011.03.009. View

14.

Gong Q, Hu Z, Zhang F, Cui A, Chen X, Jiang H . Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. Hepatology. 2016; 64(2):425-38. PMC: 5726522. DOI: 10.1002/hep.28523. View

15.

Varma V, Yao-Borengasser A, Bodles A, Rasouli N, Phanavanh B, Nolen G . Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes. 2007; 57(2):432-9. PMC: 2877915. DOI: 10.2337/db07-0840. View

16.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

17.

Gomez-Lechon M, Donato M, Martinez-Romero A, Jimenez N, Castell J, OConnor J . A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2006; 165(2):106-16. DOI: 10.1016/j.cbi.2006.11.004. View

18.

Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C . Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006; 12(24):7444-55. DOI: 10.1158/1078-0432.CCR-06-0109. View

19.

Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos M, Pardo V, Miquilena-Colina M . Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014; 5:e1179. PMC: 4001315. DOI: 10.1038/cddis.2014.162. View

20.

Tiwari S, Siddiqi S, Siddiqi S . CideB protein is required for the biogenesis of very low density lipoprotein (VLDL) transport vesicle. J Biol Chem. 2013; 288(7):5157-65. PMC: 3576120. DOI: 10.1074/jbc.M112.434258. View